Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia
Status:
Terminated
Trial end date:
2017-07-05
Target enrollment:
Participant gender:
Summary
This study consists of 2 parts: Phase 1b and Phase 2. Phase 1b will evaluate the safety and
tolerability of the combination of idelallisib with the anti-CD37 monoclonal antibody BI
836826 in participants with relapsed/refractory chronic lymphocytic leukemia (R/R CLL), and
establish the high recommended Phase 2 combination dose (highRP2D) as well as an alternate
lower recommended Phase 2 combination dose (lowRP2D). Phase 2 will determine the rates of
complete response (CR) and of minimal residual disease (MRD) negativity with the combination
at the highRP2D and the lowRP2D in participants with R/R CLL.